| Index | — | P/E | — | EPS (ttm) | -1.77 | Insider Own | — | Shs Outstand | 61.59M | Perf Week | -3.14% |
| Market Cap | 474.84M | Forward P/E | — | EPS next Y | -2.10 | Insider Trans | — | Shs Float | 39.90M | Perf Month | -11.68% |
| Enterprise Value | 476.84M | PEG | — | EPS next Q | -0.60 | Short Float | 4.48% | Perf Quarter | -35.70% | ||
| Income | -101.00M | P/S | — | EPS this Y | — | Short Ratio | 6.76 | Perf Half Y | -72.72% | ||
| Sales | 0.00 | P/B | 1.75 | EPS next Y | — | ROA | -31.82% | Short Interest | 1.79M | Perf YTD | -61.39% |
| Book/sh | 4.40 | P/C | — | EPS next 5Y | — | ROE | -42.92% | 52W High | 34.48 -77.64% | Perf Year | -61.62% |
| Cash/sh | 0.00 | P/FCF | — | EPS past 3/5Y | — | ROIC | -38.94% | 52W Low | 7.11 8.44% | Perf 3Y | -22.12% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — | Gross Margin | 35.21% | Volatility | 6.83% 5.99% | Perf 5Y | -20.60% |
| Dividend TTM | — | EV/Sales | — | EPS Y/Y TTM | — | Oper. Margin | -35874.24% | ATR (14) | 0.52 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 8.35 | Sales Y/Y TTM | — | Profit Margin | -32780.20% | RSI (14) | 37.87 | Recom | 2.00 |
| Dividend Gr. 3/5Y | — | Current Ratio | 8.35 | EPS Q/Q | 66.10% | SMA20 | -2.55% | Beta | 0.29 | Target Price | — |
| Payout | 0.00% | Debt/Eq | 0.01 | Sales Q/Q | — | SMA50 | -20.03% | Rel Volume | 0.96 | Prev Close | 8.26 |
| Employees | 60 | LT Debt/Eq | 0.01 | Earnings | Nov 03 | SMA200 | -58.86% | Avg Volume | 257.65K | Price | 7.71 |
| IPO Date | May 18, 2021 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 59.02% 73.95% | Net Debt/EBITDA | — | Volume | 246,350 | Change | -6.66% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jun-01-26 | Reiterated | Robert W. Baird | ||
| Jun-01-26 | Reiterated | Needham | Buy | |
| Jun-01-26 | Reiterated | Guggenheim | Buy | |
| Jun-01-26 | Reiterated | HC Wainwright & Co. | Buy | $26 |
| May-20-26 | Initiated | Guggenheim | Buy | |
| May-12-26 | Reiterated | HC Wainwright & Co. | Buy | |
| Mar-04-26 | Reiterated | Stifel Nicolaus | ||
| Dec-19-25 | Reiterated | Stifel Nicolaus | ||
| Oct-08-25 | Reiterated | Chardan Capital | Buy | |
| Oct-07-25 | Reiterated | HC Wainwright & Co. | Buy |
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 1 | 0 | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 59 | 0 | — | — | — | |
| Gross Profit | 0 | 0 | -58 | 0 | — | — | — | |
| Selling, General and Administrative Excl. Other | 38 | 30 | 25 | 16 | — | — | — | |
| Research and Development | 72 | 66 | 59 | 33 | — | — | — | |
| Other Operating Expense | 0 | -1 | -59 | 41 | — | — | — | |
| Operating Income | -110 | -95 | -83 | -90 | — | — | — | |
| Interest Expense | 0 | 1 | 1 | 2 | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 11 | -18 | -14 | -7 | — | — | — | |
| Net Income Before Taxes | -101 | -114 | -98 | -99 | — | — | — | |
| Income Taxes | 0 | 0 | 0 | 0 | — | — | — | |
| Consolidated Net Income | -101 | -114 | -98 | -99 | — | — | — | |
| Net Income From Continuing Operations | -101 | -114 | -98 | -99 | — | — | — | |
| Net Income | -101 | -114 | -98 | -99 | — | — | — | |
| EPS (Recurring) | -1.77 | -2.18 | -2.41 | -3.31 | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.77 | -2.18 | -2.41 | -3.31 | — | — | — | |
| EPS (Diluted) | -1.77 | -2.18 | -2.41 | -3.31 | — | — | — | |
| EBITDA | -99 | -112 | -97 | -97 | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | 680.00 | — | — | — | — | |
| Gross Margin | — | — | -5,800.00 | — | — | — | — | |
| Operating Margin | — | — | -8,300.00 | — | — | — | — | |
| Net Margin | — | — | -9,800.00 | — | — | — | — | |
| Shares Outstanding | 61 | 52 | 40 | 30 | — | — | — | |
| Market Capitalization | 470 | 1,038 | 680 | 337 | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — |